Disease Extent in Stage IV Lobular Carcinoma: the Aid of Imaging and Liquid Biopsy Analyses (DELILA)
Metastatic invasive lobular carcinoma (ILC) is a distinct breast cancer subtype characterized by loss of E-cadherin and a diffuse growth pattern that makes metastases difficult to detect with standard imaging such as computed tomography (CT) or 18F-Fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET)/CT. As a result, disease burden in patients with ILC is frequently underestimated, progression is identified later than clinically optimal, and many patients are excluded from clinical trials due to insufficiently measurable disease.
Whole-body diffusion-weighted magnetic resonance imaging (WB-DWI/MRI) is a radiation-free imaging technique that has demonstrated improved sensitivity for detecting metastases-including peritoneal, bone, and nodal disease-in ILC. Retrospective studies suggest that WB-DWI/MRI can identify clinically relevant progression not visible on standard imaging. However, prospective evidence in ILC is lacking. Circulating tumor DNA (ctDNA) has also shown promise as a minimally invasive biomarker for monitoring treatment response, with early molecular changes often preceding radiologic progression, but data specific to ILC remain limited.
The DELILA study is a prospective, multicenter clinical trial conducted at University Hospitals Leuven and Institut Jules Bordet. The study aims to enroll 43 patients starting first-line systemic therapy for metastatic hormone receptor positive human epidermal growth factor receptor 2 negative (HR+/HER2-) ILC. Participants undergo serial dual imaging-WB-DWI/MRI and standard-of-care imaging-at baseline, at 1 month, and approximately every 3 months for up to 30 months or until disease progression. At each imaging time point, blood samples are collected for ctDNA analysis and Ca15.3 tumor marker assessment. Patient-reported psychological burden related to repeated imaging and blood sampling is evaluated using validated questionnaires.
The primary objective is to assess the added value of WB-DWI/MRI in detecting disease progression that informs clinical decision-making compared to standard imaging. Secondary objectives include evaluating whether ctDNA or Ca15.3 dynamics reflect disease evolution, assessing measurability of lesions with Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and MRI-specific criteria, identifying early biomarkers of treatment response using Apparent Diffusion Coefficient (ADC) changes and ctDNA kinetics, and characterizing the psychological impact of trial procedures.
This study will provide the first adequately powered prospective evidence on the clinical utility of WB-DWI/MRI and liquid biopsy monitoring in metastatic ILC. Results may support implementation of WB-DWI/MRI as a routine imaging strategy, guide imaging frequency through biomarker-informed approaches, and improve patient experience and trial eligibility for individuals living with metastatic ILC.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures
- At least 18 years of age at the time of signing the Informed Consent Form (ICF)
- ECOG from 0 to 2
- Patient with stage IV ILC, either de novo or after prior (curative) treatment for early ILC. Histological subtype confirmed on primary tumor or on metastatic tissue. Patients that are diagnosed with stage IV breast cancer that have a mixed ILC/IBC-NST histology of the primary tumor (mixed histology within the same primary lesion) will also be able to participate and will be analyzed in an exploratory cohort.
- Confirmation of hormone receptor positive (HR+)/HER2- disease either on new biopsy or archival tissue (e.g. primary tumor)
- Multifocal or bilateral disease is allowed if all evaluated foci present with HR+/HER2- ILC
- Starting first line of treatment for metastatic ILC
Exclusion Criteria:
- Presence of a contraindication to perform WB-DWI/MRI
- Presence of severe claustrophobia
- Presence of a contraindication to use IV contrast for CT or PET/CT (e.g. allergy, severe renal failure) in case a non-contrast PET/CT cannot be performed
- Patients considered to have oligometastatic disease who are expected to undergo locoregional treatment
- Presence of other malignancies in recent medical history (<5 years)
- Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate, highly effective contraceptive
- Adults who are the subject of a legal protection measure or who are unable to express their consent.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Diagnostisch
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Standard-of-care Imaging + Whole-body diffusion-weighted MRI
Participants will undergo dual imaging at baseline and then every three months during first-line treatment for metastatic ILC, continuing until either 30 months of follow-up or documented disease progression.
At these same timepoints, ctDNA levels and Ca15.3 will also be assessed.
|
Frequency: at baseline, after 1 month and every 3 months until 30 months of follow-up or disease progression
Frequency: at baseline, after 1 month and every 3 months until 30 months of follow-up or disease progression
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Percentage of cases where WB-DWI/MRI contributed solely to the decision of progression and/or treatment change assessed by questionnaires filled out by the treating oncologist at the time of progression
Tijdsspanne: At the time of progression
|
At the time of progression
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
ctDNA dynamics
Tijdsspanne: At baseline, after 1 month of treatment, and every 3 months of treatment until disease progression or a maximum follow-up of 30 months (end of trial).
|
ctDNA levels will be assessed at baseline and every 3 months.
Changes in levels will be correlated with findings on imaging.
|
At baseline, after 1 month of treatment, and every 3 months of treatment until disease progression or a maximum follow-up of 30 months (end of trial).
|
|
Measurability according to RECISTv1.1 criteria
Tijdsspanne: At baseline and every 3 months of treatment until disease progression or a maximum follow-up of 30 months (end of trial).
|
At baseline and every 3 months of treatment until disease progression or a maximum follow-up of 30 months (end of trial).
|
|
|
Measurability according to MRI-specific criteria
Tijdsspanne: At baseline and every 3 months of treatment until disease progression or a maximum follow-up of 30 months (end of trial).
|
Measurability will be assessed on MRI by use of RECIST v1.1 criteria and RECISTv1.1 extended with MRI-specific criteria (similar to MY-RADS and MET-RADS-P).
|
At baseline and every 3 months of treatment until disease progression or a maximum follow-up of 30 months (end of trial).
|
|
Disease extent on WB-DWI/MRI compared to SOC imaging
Tijdsspanne: At baseline and every 3 months of treatment until disease progression or a maximum follow-up of 30 months (end of trial).
|
Disease extent on whole-body DWI/MRI (WB-DWI/MRI) is analyzed and compared with standard-of-care (SOC) imaging (e.g., CT, PET/CT, bone scan) using a combination of lesion detection, segmentation, and quantitative scoring methods.
First, all visible lesions are identified on WB-DWI/MRI and SOC images using predefined anatomical regions.
Lesions are counted and, where feasible, segmented to estimate tumor burden (e.g., total tumor volume).
|
At baseline and every 3 months of treatment until disease progression or a maximum follow-up of 30 months (end of trial).
|
|
Lesion-level ADC dynamics
Tijdsspanne: At baseline and after 1 month of treatment
|
Quantitative assessment using ADC measurements will be incorporated to support treatment response evaluation.
Diffusion-weighted images acquired at baseline and early follow-up are used to generate ADC maps; the lesion is segmented, and quantitative metrics (e.g., mean or percentile ADC) are extracted.
The change in ADC (absolute or percentage) is then calculated, with a significant increase typically indicating response, while stable or decreased ADC suggests resistance.
|
At baseline and after 1 month of treatment
|
|
Scores of psychological assessment questionnaires compared to baseline
Tijdsspanne: At baseline, after 1 month of treatment, and every 3 months of treatment until disease progression or a maximum follow-up of 30 months (end of trial).
|
Anxiety related to the imaging modalities will be assessed using the STAI-6 and Likert-10 scales, including evaluation of potential stressors associated with each imaging technique.
The EORTC QLQ-COMU26 questionnaire will be used to assess patients' perceptions of imaging-related communication.
|
At baseline, after 1 month of treatment, and every 3 months of treatment until disease progression or a maximum follow-up of 30 months (end of trial).
|
|
Scores of psychological assessment questionnaires compared between imaging modalities
Tijdsspanne: At baseline and every 3 months of treatment until disease progression or a maximum follow-up of 30 months (end of trial).
|
Anxiety related to the imaging modalities will be assessed using the STAI-6 and Likert-10 scales, including evaluation of potential stressors associated with each imaging technique.
The EORTC QLQ-COMU26 questionnaire will be used to assess patients' perceptions of imaging-related communication.
|
At baseline and every 3 months of treatment until disease progression or a maximum follow-up of 30 months (end of trial).
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Hans Wildiers, MD/PHD, UZ Leuven
- Hoofdonderzoeker: Philippe Aftimos, MD, Jules Bordet Institute
- Hoofdonderzoeker: Elia Biganzoli, PHD, University of Milan
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- S71975
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .